HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

rebemide

insect repellent; RN given refers to parent cpd
Also Known As:
N,N-diethylbenzamide; rebeftal; rebemide hydrochloride
Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Folk, John E: 2 articles (01/2012 - 10/2006)
2. Negus, S Stevens: 2 articles (01/2012 - 10/2006)
3. Rice, Kenner C: 2 articles (01/2012 - 10/2006)
4. Agius, Paul A: 1 article (01/2020)
5. Barry, Alyssa E: 1 article (01/2020)
6. Beeson, James G: 1 article (01/2020)
7. Crabb, Brendan S: 1 article (01/2020)
8. Cutts, Julia C: 1 article (01/2020)
9. Devine, Angela: 1 article (01/2020)
10. Fowkes, Freya J I: 1 article (01/2020)

Related Diseases

1. Hypokinesia (Bradykinesia)
2. Hyperalgesia
11/01/2013 - "Here we examined the effects of intrathecal SNC80 [(+)-4-[α(R)-α-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-(methoxybenzyl)-N,N-diethylbenzamide], a selective nonpeptidic DOR agonist, in three preclinical pain models, acute thermal escape, intraplantar carrageenan-tactile allodynia, and intraplantar formalin flinches, and on the evoked release of substance P (SP) from small primary afferents. "
09/01/2002 - "Morphine (mu-agonist), [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]-enkephalin (mu-agonist; DAMGO), 4-[((alpha)R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (delta-agonist; SNC80), or (1S-trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cylcohexyl]-benzeneacetamide hydrochloride (kappa-agonist; U50,488) were administered intrathecally to activate opioid receptors once hyperalgesia was developed. "
01/01/2012 - "This study examined interactions between the delta agonist SNC80 [(+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and the mu agonist analgesics methadone, morphine, and nalbuphine in an assay of capsaicin-induced thermal allodynia in rhesus monkeys. "
11/24/2010 - "We found that: (1) intradermal injection of both the endogenous ligand for the Ret receptor, glia-derived growth factor (GDNF), and the ligand for the tropomyosin receptor kinase A (TrkA) receptor, nerve growth factor (NGF)-which are present on distinct populations of nociceptors-both produce mechanical hyperalgesia; (2) DOR agonist 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide (SNC) but not MOR agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) inhibit GDNF-induced hyperalgesia; (3) both DAMGO and SNC inhibit NGF hyperalgesia, even in rats pretreated with isolectin B4 (IB4)-saporin, a toxin that destroys IB4-binding neurons; (4) co-administration of low doses of DAMGO and SNC produce enhanced analgesia, and; (5) repeated administration of DAMGO produces cross-tolerance to the analgesic effect of SNC. "
3. Infections
4. Cocaine-Related Disorders (Cocaine Addiction)
5. Pain (Aches)

Related Drugs and Biologics

1. 4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamide
2. Oxidopamine (6 Hydroxydopamine)
3. Morphine (MS Contin)
4. Analgesics (Analgesic Drugs)
5. Nalbuphine (Nubain)
6. Methadone (Dolophine)
7. Capsaicin (Zostrix)
8. Ala(2)-MePhe(4)-Gly(5)- Enkephalin (DAGO)
9. Enkephalins
10. Glial Cell Line-Derived Neurotrophic Factor (GDNF)

Related Therapies and Procedures

1. Intradermal Injections
2. Analgesia